Pharmacokinetics and metabolism of docetaxel administered as a 1-h intravenous infusion

Cancer Chemotherapy and Pharmacology

Volumn 45, Issue 3, 2000, Pages 213-218

  Rosing, H ^a   Lustig, V ^b   Van Warmerdam, L J C ^a   Huizing, M T ^a   Ten Bokkel Huinink, W W ^c   Schellens, J H M ^c   Rodenhuis, S ^c   Bult, A ^d   Beijnen, J H ^a,c,d  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b Flevo Hospital   (Netherlands)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

^d UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Docetaxel; Metabolism; Pharmacodynamics; Pharmacokinetics; Taxotere

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; DOCETAXEL;

ADULT; AGED; ALOPECIA; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; DOSE CALCULATION; DRUG METABOLISM; DRUG MONITORING; DRUG STRUCTURE; EDEMA; FEMALE; FLUID RETENTION; HUMAN; MALE; NEUTROPENIA; PRIORITY JOURNAL;

EID: 0033974846     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050032     Document Type: Article

References (18)

1. 1. Bissett D, Setanoians A, Cassidy J, Graham MA, Chadwick GA, Wilson P, Auzannet V, Le Bail N, Kaye SB, Kerr DJ (1993) Phase I and pharmacokinetic study of Taxotere (RP 56976) administered as a 24 hour infusion. Cancer Res 53: 523-527
2. 2. Bruno R, Vivier N, Vergniol JC, De Philips SL, Montay G, Sheiner LB (1996) A population pharmacokinetic model for docetaxel (Taxotere®): method building and validation. J Pharmacokinet Biopharm 2: 153-172
3. 3. Bruno R, Riva A, Hille D, Lebecq A, Thomas L (1997) Pharmacokinetic and pharmacodynamic properties of docetaxel: results of phase I and phase II trials. Am J Health Syst Pharm 54 [Suppl 2]: 16-19
4. 4. Bruno R, Hille D, Riva A, Vivier N, ten Bokkel Huinink WW, van Oosterom AT, Kaye SB, Verweij J, Fossella FV, Valero V, Rigas JR, Seidman AD, Chevallier B, Fumoleau P, Burris HA, Ravdin PM, Sheiner LB (1998) Population pharmacokinetics/ pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 16: 187-196
5. 5. Burris H, Irvin R, Kuhn J, Kalter S, Smith L, Shaffer D, Fields S, Weiss G, Eckhardt J, Roderiguez G, Rinaldi D, Wall J, Cook G, Smith S, Vreeland F, Bayssas M, Le Bail N, Von Hoff D (1993) Phase I clinical trial of Taxotere administered as either a 2 hour or 6 hour intravenous infusion. J Clin Oncol 11: 950-958
6. 6. Colin M, Guénard D, Guéritte-Voegelein F, Potier P (1989) Taxol derivatives, their preparation and pharmaceutical conditions containing them. Patent 4,814,470, 21 March 1989. U.S. Patent office, Washington, DC
7. 7. Extra JM, Rousseau F, Bruno R, Clavel M, Le Bail N, Marty M (1993) Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion. Cancer Res 53: 1037-1042
8. 8. Launay-Iliadis MC, Bruno R, Cosson V, Vergniol VC, Oulid-Aissa D, Marty M, Clavel M, Aapro M, Le Bail N, Iliadis A (1995) Population pharmacokinetics of docetaxel during phase I studies using nonlinear mixed-effects modeling and non-parametric maximum-likelihood estimation. Cancer Chemother Pharmacol 37: 47-54
9. 9. Loos WJ, Verweij J, Nooter K, Stoter G, Sparreboom A (1997) Sensitive determination of docetaxel in human plasma by liquid-liquid extraction and reversed-phase high-performance liquid chromatography. J Chromatogr B 693: 437-441
10. 10. Lustig V, Rosing H, van Warmerdam LJC, Huizing MT, ten Bokkel Huinink WW, Dubbelman AC, Beijnen JH (1997) Limited sampling models for the pharmacokinetics of docetaxel. Clin Drug Invest 13: 247-254
11. 11. Monegier B, Gaillard C, Sablé S, Vuilhorgne M (1994) Structures of the major human metabolites of docetaxel (RP 56976 -Taxotere®). Tetrahedron Lett 35: 3715-3718
12. 12. Pazdur R, Newman RA, Newman BM, Fuentes A, Benvenuto J, Bready B, Moore D Jr, Jaiyesimi I, Vreeland F, Bayssas MMG, Raber MN (1992) Phase I trial of Taxotere: five-day schedule. J Natl Cancer Inst 84: 1781-1788
13. 13. Proost JH, Meijer DKF (1992) MW/PHARM, an integrated software package for drug dosage regimen calculations and therapeutic drug monitoring. Comput Biol Med 22: 155-163
14. 14. Rosing H, Lustig V, Koopman FJ, ten Bokkel Huinink WW, Beijnen JH (1997) Bio-analysis of docetaxel and hydroxylated metabolites in human plasma by high-performance liquid chromatography and automated solid-phase extraction. J Chromatogr B 696: 89-98
15. 15. Sparreboom A, van Tellingen O, Scherrenburg EJ, Boesen JJB, huizing MT, Nooijen WJ, Versluis C, Beijnen JH (1996) Isolation, purification and biological activity of major docetaxel metabolites from human feces. Drug Metab Dispos 24: 655-958
16. 16. Tomiak E, Piccart MJ, Kerger J, Lips S, Awada A, de Valeriola D, Ravoet C, Lossignol D, Sculier JP, Auzannet V, Le Bail N, Bayssas M, Klastersky J (1994) Phase I study of docetaxel administered as a 1 hour intravenous infusion on a weekly basis. J Clin Oncol 12: 1458-1467
17. 17. Vergniol JC, Bruno R, Montay G, Frydman A (1992) Determination of Taxotere in human plasma by a semi-automated high-performance liquid Chromatographic method. J Chromatogr B 582: 273-278
18. 18. Zhou-Pan XR, Marre F, Zhou XJ, Gauthier T, Placidi M, Rahmani R (1993) Preliminary characterisation of taxotere metabolism by using human liver microsomal fractions. Cell Pharmacol [Suppl] 1: 119